CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus

Exclusion Criteria

• •Severe active vasculitis, active central nervous system lupus, active lupus nephritis, uncontrolled hypertension or poorly controlled diabetes
• •Malignancy within past 5 years
• •Known to be positive for HIV and/or positive at the screening visit for hepatitis B, or hepatitis C
• •Liver disease
• •Anemia, neutropenia, or thrombocytopenia
• •Active infection requiring hospitalization or treatment with parenteral antibiotics within the past 60 days or history of repeated herpetic viral infections
• •History of active tuberculosis or a history of tuberculosis infection
• •Pregnant or nursing